Anemia Clinical Trials

Find Anemia Clinical Trials Near You

Morphine Clearance and Glomerular Filtration in Sickle Cell Patients in Crisis in Intensive Care

Status: Recruiting
Location: See all (6) locations...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY

Background: Sickle cell disease is a genetic disorder of haemoglobin (which carries oxygen in red blood cells). The shape of sickle cell-patients' red blood cells is abnormal. Thus, red blood cells can be blocked in small vessels, responsible for painful crises due to a lack of downstream circulation. These crisis (acute vaso-occlusive crisis) require strong treatment based on morphine, and often require intensive care.However, treatment is often insufficiently effective. Patient can also experiment acute chest syndrome, a complication of vaso-occlusive crisis, which can be responsible for respiratory failure. In addition, patients with sickle cell disease frequently have kidney damage called sickle cell nephropathy, which in the early stages of the disease is responsible for renal hyperfiltration, meaning that the kidneys filter the blood more than necessary, with faster elimination of drugs. For example, it is known that higher doses of antibiotics must be used in these patients than in the general population for the same effectiveness. The hypothesis of the study is that morphine, a drug eliminated by kidneys, is underdosed in patients with sickle cell disease, which is responsible for the difficulties in achieving sufficient analgesia.

Objective: To determine the glomerular filtration rate threshold for which it is necessary to prescribe higher doses of morphine in sickle cell patients with vaso-occlusive crisis.

Methods: inclusion of 100 patients admitted to intensive care for an acute vaso-occlusive crisis or acute chest syndrome and receiving morphine. Within 24 hours of study inclusion, four morphine dosages will be performed, in parallel with a precise determination of the glomerular filtration rate by measuring the elimination rate of a tracer, 100% eliminated by the kidneys and injected at the start of the study. This tracer is iohexol, a contrast agent commonly used in radiology. Morphine underdosage will be interpretated regarding glomerular filtration rate. The effectiveness of analgesia and the amount of analgesics required will be also be analyzed. Outlook: At the end of this study, the investigators will be able to offer adapted doses of morphine for sickle cell patients in crisis, adapted to glomerular filtration rate, in the aim of personalizing analgesia.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:

• Patient ≥ 18 years old

• Known homozygous sickle cell disease SS, SC, S-beta+, or S-beta0

• Admitted in an intensive care unit

• Clinical diagnosis of vaso-occlusive crisis and/or acute chest syndrome

• Receiving PCA treatment with morphine

• Patient's consent for study participation and/or from a relative if case of patient's incapacity

• Affiliation to social protection

Locations
Other Locations
France
Henri-Mondor
NOT_YET_RECRUITING
Créteil
CH Le Mans
NOT_YET_RECRUITING
Le Mans
CHU de Nantes
NOT_YET_RECRUITING
Nantes
CHU d'Orléans
NOT_YET_RECRUITING
Orléans
CHU de Rennes
NOT_YET_RECRUITING
Rennes
CHRU de Tours
RECRUITING
Tours
Contact Information
Primary
Charlotte SALMON-GANDONNIERE, MD
charlotte.salmon.gandonniere@gmail.com
+33 2 47 47 38 55
Backup
Coralie TAILLEBUIS
cpcq@chu-tours.fr
+332 47 47 39 09
Time Frame
Start Date: 2026-03-05
Estimated Completion Date: 2028-09
Participants
Target number of participants: 100
Treatments
Experimental: Determination of glomerular filtration rate by Iohexol
Four morphine dosages, and a precise determination of the glomerular filtration rate by the measure of the elimination rate of iohexol will be carried out. The investigators will analyse in which patients and for which glomerular filtration rate there is morphine underdosage and simultaneously evaluate the effectiveness of analgesia and the amount of analgesics required.
Sponsors
Leads: University Hospital, Tours

This content was sourced from clinicaltrials.gov